Be Biopharma debuts with $52M to advance engineered B-cell therapies

You may have heard of T cells, but Aleks Radovic-Moreno, Ph.D., Be Biopharma’s co-founder, president and director, is betting on B cells as the future of cell therapies.

“Our mission is to develop what we see as a new class of cell medicines that have a broad new pharmacology,” he said of B cells’ potential. “We think it's a big new white space that's enabled by the rich biology of these cells.”

The Cambridge, Massachusetts-based company is capitalizing early on research by scientists at the University of Washington School of Medicine. With a $52 million series A round in the bank, it's making a beeline for the clinic.